Literature DB >> 14521608

Aspirin and salicylate inhibit colon cancer medium- and VEGF-induced endothelial tube formation: correlation with suppression of cyclooxygenase-2 expression.

M I Shtivelband1, H S Juneja, S Lee, K K Wu.   

Abstract

To determine whether aspirin and salicylate suppress colon cancer cell-mediated angiogenesis, we evaluated the effects of aspirin and sodium salicylate on endothelial tube formation on Matrigel. Aspirin and sodium salicylate concentration-dependently inhibited human endothelial cell (EC) tube formation induced by conditioned medium collected from DLD-1, HT-29 or HCT-116 colon cancer cells. Aspirin and sodium salicylate at pharmacological concentrations were equally effective in blocking tube formation. Neutralizing antivascular endothelial growth factor (VEGF) antibodies blocked colon cancer medium-induced tube formation. VEGF receptor 2 but not receptor 1 antibodies inhibited tube formation to a similar extent as anti-VEGF antibodies. These results indicate that VEGF interaction with VEGF receptor 2 is the primary mechanism underlying colon cancer-induced angiogenesis. Aspirin or sodium salicylate inhibited VEGF-induced tube formation in a concentration-dependent manner comparable to that of inhibition of colon cancer medium-induced endothelial tube formation. It has been shown that cyclooxygenase-2 (COX-2) is pivotal in cancer angiogenesis. We found that colon cancer medium-induced COX-2 protein expression in EC and aspirin or sodium salicylate suppressed the cancer-induced COX-2 protein levels at concentrations correlated with those that suppressed endothelial tube formation. Furthermore, aspirin and sodium salicylate inhibited COX-2 expression stimulated by VEGF. These findings indicate that aspirin and other salicylate drugs at pharmacological concentrations inhibit colon cancer-induced angiogenesis which is correlated with COX-2 suppression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14521608     DOI: 10.1046/j.1538-7836.2003.00446.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

1.  Low molecular weight heparin and aspirin exacerbate human endometrial endothelial cell responses to antiphospholipid antibodies.

Authors:  Zola Chihombori Quao; Mancy Tong; Elena Bryce; Seth Guller; Lawrence W Chamley; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2017-11-14       Impact factor: 3.886

Review 2.  Omega-3 fatty acids and the regulation of expression of endothelial pro-atherogenic and pro-inflammatory genes.

Authors:  R De Caterina; M Massaro
Journal:  J Membr Biol       Date:  2005-07       Impact factor: 1.843

3.  Pre-clinical effects of metformin and aspirin on the cell lines of different breast cancer subtypes.

Authors:  Maria Eduarda Azambuja Amaral; Laura Roesler Nery; Carlos Eduardo Leite; Walter Filgueira de Azevedo Junior; Maria Martha Campos
Journal:  Invest New Drugs       Date:  2018-02-02       Impact factor: 3.850

4.  TGF-β1 mediates the effects of aspirin on colonic tumor cell proliferation and apoptosis.

Authors:  Yuyi Wang; Chi Du; Nan Zhang; Mei Li; Yanyang Liu; Maoyuan Zhao; Feng Wang; Feng Luo
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

5.  ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor.

Authors:  P F T Cezar-de-Mello; A M Vieira; V Nascimento-Silva; C G Villela; C Barja-Fidalgo; I M Fierro
Journal:  Br J Pharmacol       Date:  2008-01-14       Impact factor: 8.739

6.  VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis.

Authors:  Nicky D'Haene; Sébastien Sauvage; Calliope Maris; Ivan Adanja; Marie Le Mercier; Christine Decaestecker; Linda Baum; Isabelle Salmon
Journal:  PLoS One       Date:  2013-06-17       Impact factor: 3.240

7.  HSPA12B: a novel facilitator of lung tumor growth.

Authors:  He Ma; Ting Lu; Xiaojin Zhang; Chuanfu Li; Jingwei Xiong; Lei Huang; Ping Liu; Yuehua Li; Li Liu; Zhengnian Ding
Journal:  Oncotarget       Date:  2015-04-30

8.  Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy.

Authors:  Chris E Holmes; Jagoda Jasielec; Jamie E Levis; Joan Skelly; Hyman B Muss
Journal:  Clin Transl Sci       Date:  2013-05-15       Impact factor: 4.689

9.  Aspirin, a Potential GLUT1 Inhibitor in a Vascular Endothelial Cell Line.

Authors:  Yabo Hu; Xiaohan Lou; Ruirui Wang; Chanjun Sun; Xiaomeng Liu; Shuochuan Liu; Zibing Wang; Chen Ni
Journal:  Open Med (Wars)       Date:  2019-09-12

10.  Aspirin inhibits colon cancer cell and tumor growth and downregulates specificity protein (Sp) transcription factors.

Authors:  Satya Pathi; Indira Jutooru; Gayathri Chadalapaka; Vijayalekshmi Nair; Syng-Ook Lee; Stephen Safe
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.